Clinical Trials Logo

Filter by:
NCT ID: NCT02959242 Recruiting - Glaucoma Clinical Trials

Dresden Glaucoma and Treatment Study (DGTS)

Start date: January 2006
Phase:
Study type: Observational

To assure the quality of follow-up and treatment, data of glaucoma patients are stored and evaluated after anonymisation.

NCT ID: NCT02957552 Recruiting - Clinical trials for Pediatric Liver Transplantation

Safety and Tolerance of Immunomodulating Therapy With Donor-specific MSC in Pediatric Living-Donor Liver Transplantation

MYSTEP1
Start date: March 10, 2017
Phase: Phase 1
Study type: Interventional

Since the introduction of calcineurin-based immunosuppression, patient and graft survival in pediatric liver transplantation (LT) improved significantly. However, in contrast, calcineurin inhibitor (CNI) toxicity leads to significant morbidity and impairs quality of life for recipients. Moreover, CNI cannot prevent long-term allograft inflammation and fibrosis. Mesenchymal stem (stromal) cells (MSC) have potent immunomodulatory properties potentially promoting allograft tolerance and ameliorating toxicity of exposure to high dose CNI. Previous trials for non-solid organ transplant indications have shown an excellent safety profile of intravenous MSC application. The MYSTEP1 trial aims to investigate safety and benefits portal and intravenous MSC infusion in pediatric LT.

NCT ID: NCT02957175 Recruiting - Clinical trials for Systemic Inflammatory Response Syndrome

Immunophenotyping of Patients With Postoperative SIRS

Start date: November 2016
Phase:
Study type: Observational

The purpose of this study is to develop an immune-phenotype based prediction of postoperative SIRS in patients undergoing open heart surgery.

NCT ID: NCT02954094 Recruiting - Clinical trials for Hepatocellular Cancer

A Longitudinal Observational Study of the Natural History and Management of Patients With HCC

Start date: December 2016
Phase:
Study type: Observational [Patient Registry]

TARGET-HCC is a longitudinal, observational study of patients being managed for HCC in usual clinical practice. TARGET-HCC will create a research registry of participants with HCC within academic and community real-world practices in order to assess the safety and effectiveness of the entire spectrum of current and future therapies across diverse populations.

NCT ID: NCT02940093 Recruiting - Clinical trials for Stem Cell Transplantation

Pipeline Integrating Gut Metagenome Data, Host Immunogenetic Characteristics and Clinical Gut Inflammatory Biomarkers

ImMiGeNe
Start date: November 24, 2016
Phase: N/A
Study type: Observational

The combined analysis of microbiome, immunological parameters and host genetics in patients has potential for applying personalized approaches of prevention, diagnostics or therapy in the future. However, the acquisition and analysis of these patient characteristics in a scientifically sound, technically reliable, cost-effective, practicable and future-oriented fashion are a far from trivial task. Therefore the objectives of the study are (i) to optimize a sample and data acquisition and analysis pipeline that fulfills these criteria (using samples from healthy volunteers); (ii) validate the pipeline in a cohort of children undergoing stem cell transplantation, yielding information on host immuno-genetics, gut immune function and the human gut microbiome; (iii) deduct the most critical parameters for host-microbiome interplay from this complex dataset.

NCT ID: NCT02938299 Recruiting - Malignant Melanoma Clinical Trials

Neoadjuvant L19IL2/L19TNF- Pivotal Study

Pivotal
Start date: July 1, 2016
Phase: Phase 3
Study type: Interventional

Phase III, open-label, randomized, controlled multi-center study of the efficacy of L19IL2/L19TNF neoadjuvant intratumoral treatment in Stage III B/C melanoma patients.

NCT ID: NCT02936765 Recruiting - Clinical trials for Intervertebral Disc Displacement

Comparison of Software-assisted Implantation of Elastic Spine Pad (TM) With Respect to Postoperative Change in Neck Disability Index (NDI) With the Conventional Disc Spacer Squale (TM) After Anterior Cervical Discectomy for Cervical Disc Prolapse

Start date: June 2016
Phase: N/A
Study type: Interventional

This is an investigator-initiated study. The primary goal is to evaluate the efficacy of two different cervical disc devices (prosthesis vs rigid spacer) with respect to postoperative change in neck disability index. The evaluation will include clinical and radiological parameters.

NCT ID: NCT02936739 Recruiting - Clinical trials for Intervertebral Disc Displacement

Comparison of Software-assisted Implantation of Elastic Spine Pad (TM) With Respect to Postoperative Change in Neck Disability Index (NDI) With the Conventional Disc Prosthesis Rotaio (TM) After Anterior Cervical Discectomy for Cervical Disc Prolapse

Start date: June 2016
Phase: N/A
Study type: Interventional

This is an investigator-initiated study. The primary goal is to evaluate the efficacy of two different cervical disc prosthetic devices with respect to postoperative change in neck disability index. The evaluation will include clinical and radiological parameters.

NCT ID: NCT02936388 Recruiting - Uveal Melanoma Clinical Trials

Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis

SirTac
Start date: January 2016
Phase: Phase 2
Study type: Interventional

Characterisation of effect of SIRT and DSM-TACE as local treatment options for liver metastases in patients with advanced uveal melanoma with respect to progression-free survival and exploratory comparison of secondary endpoints regarding application, activity, adverse effects and impact on quality of life in a randomized study design.

NCT ID: NCT02932618 Recruiting - Clinical trials for Von Willebrand Disease

A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

Start date: December 18, 2017
Phase: Phase 3
Study type: Interventional

The main aim of the study is to check effectiveness, side effects, and tolerability of recombinant von Willebrand Factor (rVWF), with or without ADVATE, in the treatment and control of nonsurgical bleeding events in pediatric participants (less than (<)18 years of age) with severe hereditary von Willebrand disease (VWD). The participants will be treated with rVWF for 12-18 months. Their von Willebrand Disease will be treated by their doctor according to their doctor's usual clinical practice. During the study, participants will be followed up at clinics or over telephone calls.